Highlights Medigene AG OTC Markets

Equities

MDGEF

DE000A1X3W00

Market Closed - OTC Markets Other stock markets 14:36:56 28/03/2024 GMT			5-day change	1st Jan Change
2.297 ^USD	-11.96%		-5.49%	+53.10%

07-03	Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China	CI
06-27	Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China	07-03	CI
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	06-27	CI
Medigene, BioNTech Extend Cancer Immunotherapy Partnership	05-21	MT
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term	05-21	CI
Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	05-15	CI
Medigene Ag Maintains Earnings Guidance for 2024	05-14	CI
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	05-02	CI
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	05-02	CI
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	04-25	CI
Rights Issue: 1 new share @ 1.2 EUR for 5 existing shares	04-23	FA
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	04-08	CI
Medigene Gets European Patent for T-Cell Receptor Technology	04-04	MT
Medigene AG Secures European Patent for Its iM-TCR Technology	04-04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Medigene Ag Provides Earnings Guidance for 2024	03-28	CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	03-04	CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	02-12	CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	11-21	CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	11-04	CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23/10/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Medigene AG OTC Markets

Equities

MDGEF

DE000A1X3W00

Highlights

Filters